Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-150 vs Aflibercept in nAMD
NCT07064759Phase 3Recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Jul 2025
- Primary completion
- Nov 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 17
01
Overview
A Phase 3 trial of 4D-150 in neovascular age-related macular degeneration (NVAMD), sponsored by 4D Molecular Therapeutics. Started Jul 2025; status: recruiting.
02
Drugs
4D-150
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07064759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064759.